非靶标和靶标代谢组学技术在肺癌诊断血清标志物筛选中的应用

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application value of non-target and target metabolomics technology in the screening of serum markers in lung cancer diagnosis.Methods Based on 1HNMR metabolomics,47 cases of post-operative lung cancer tissues and their corresponding normal lung tissue samples from the First Affiliated Hospital of Nanchang University and Jingdezheng NO.1 People′s Hospital were determined to identify their metabolites and obtain the differential metabolites related to the diagnosis of lung cancer from July 2017 to December 2018.The quantitative analysis of related metabolites in serum of 143 lung cancer patients and 99 healthy control group was carried out by ultra performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS).The excellent metabolite combinations for lung cancer diagnosis were screened based on Logistic regression analysis and receiver operating characteristic curve.Results 1HNMR metabolomics analysis showed that lipids,lactic acid and betaine were differentially metabolites related to lung cancer tissues and normal tissues,suggesting that methylation-related metabolites might be related to the diagnosis of lung cancer.The results of UPLC-MS/MS quantitative analysis showed that the serum samples of lung cancer andhealthy group had significant statistical differences in cystathionine,carnitine,acetyl carnitine,xanthylinucleic acid,guanosine,guanine,inosine,creatinine,uridine,choline,adenine,dimethyl-glycine,adenosine and uric acid (P＜0.05).The combined area under the curve of cystathionine,guanosine,uric acid and adenine was 0.993,with high sensitivity and specificity (＞85%).Conclusion The combination of non-target and target metabolomics techniques to determine serum adenine,guanosine,uric acid and cystathionine can be used as a potential serum marker for the diagnosis of lung cancer and is worthy of further clinical confirmation and research.

Key words： Diagnosis of lung cancer;Markers;Metabonomics HNMR UPLC-MS/MS

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Wei-liang
	YU Jiang-qing
	DU Fen
	XIE Bao-gang
	HE Xiang-yuan3

Cite this article:

ZHENG Wei-liang,YU Jiang-qing,DU Fen, et al. Application of non-target and target metabolomics techniques in the screening of serum markers for the diagnosis of lung cancer[J]. 中国当代医药, 2020, 27(31): 4-8.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I31/4

[2]	Bamji-Stocke S，Van Berkel V，Miller DM，et al.A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment[J].Metabolomics，2018，14（6）：81.
[3]	Lin Y，Leng Q，Jiang Z，et al.A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules[J].Int J Cancer，2017，141（6）：1240-1248.
[4]	Jacobson L，Austin JH，Field JK，et al.Development of the American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America：recommendations of the American Association for Thoracic Surgery Task Force for lung cancer screening and surveillance[J].J Thoracic Cardiovasc Surg，2012，144（1）：25-32.
[5]	Zhang A，Sun H，Wang P，et al.Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity[J].Pharmazie，2012，67（2）：99-105.
[6]	Yazdani H，Yazdani A，Cheng L，et al.Bounded Fuzzy Possibilistic Method reveals information about lung cancer through analysis of metabolomics[J].IEEE/ACM Trans Comput Biol Bioinform，2020，17（2）：526-535.
[7]	Klupczynska A，Derezinski P，Garrett TJ，et al.Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics[J].J Cancer Res Clin Oncol，2017，143（4）：649-659.
[8]	Chen Y，Ma Z，Min L，et al.Biomarker identification and pathway analysis by serum metabolomics of lung cancer[J].Biomed Res Int，2015，20（15）：601-624.
[1]	Jemal A，Bray F，Center MM，et al.Global cancer statistics[J].CA Cancer J Clin，2011，61（2）：69-90.
[10]	Peng F，Liu Y，He C，et al.Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC-MS metabolomics approach[J].J Pharm Biomed Anal，2018，154（6）：95-101.
[11]	Rocha CM，Carrola J，Barros AS，et al.Metabolic signatures of lung cancer in biofluids：NMR-based metabonomics of blood plasma[J].J Proteome Res，2011，10（9）：4314-4324.
[12]	Choi SY，Collins CC，Gout PW，et al.Cancer -generated lactic acid：a regulatory，immunosuppressive metabolite?[J].J Pathol，2013，230（4）：350-355.
[13]	Gillies RJ，Gatenby RA.Metabolism and its sequelae in cancer evolution and therapy[J].Cancer J，2015，21（2）：88-96.
[14]	Li YJ，Song X，Zhao XJ，et al.Seru m metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry[J].J Chromatogr B Analyt Technol Biomed Life Sci，2014，966（1）：147-153.
[15]	Kappock TJ，Ealick SE，Stubbe J，et al.Modular evolution of the purine biosynthetic pathway[J].Curr Opin Chem Biol，2000，4（5）：567-572.
[16]	余欣尉，吴谦，吕望，等.基于液相色谱-质谱联用技术的肺癌细胞代谢组学分析[J].色谱，2013，31（7）：691-696.
[17]	Pons R，Devivo DC.Primary and secondary carnitine deficiency syndromes[J].J Child Neurol，1995，10（2）：8-24.
[18]	Guiraud SP，Montoliu I，Da Silva L，et al.High-throughput and simultaneous quantitative analysis of homocysteinemethionine cycle metabolites and co-factors in blood plasma and cerebrospinal fluid by isotope dilution LC-MS/MS[J].Anal Bioanal Chem，2017，409（1）：295-305.
[19]	Stinkens K，Vanhove K，Thomeer M，et al.Metabolomics a novel biomarker in lung cancer[J].J Thorac Oncol，2015，10（6）：36-46.
[20]	Zhang X，Zhu X，Wang C，et al.Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis[J].Oncotarget，2016，7（39）：63 437-63 448.
[9]	牛艳洁，江银玲，许长江，等.代谢组学方法分析肺癌患者血清和尿液小分子代谢产物的初步研究[J].中国肺癌杂志，2012，15（4）：195-201.